10X RIPA Lysis Buffer

• Catalog Number: orb420112
• Category: Tools
• Description: RIPA Lysis Buffer
• Tested applications: ChIP, IP, WB
• Concentration: 10X
• Dilution range: IP: User Optimized, WB: User Optimized
• Form/Appearance: Liquid (sterile filtered)
• Purity: This product was aseptically filtered through a Millipore 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria.
• Conjugation: Unconjugated
• Hazard Information: Non-Toxic
• Storage: Store container at room temperature (18° to 26° C) prior to opening. Protect from light (store in the dark).
• Buffer/Preservatives: 0.01% (w/v) Sodium Azide
• Alternative names: 10X RIPA Lysis Buffer, RIPA (Radio-Immunoprecipita
• Note: For research use only
• Application notes: This product is 10X concentrated stock solution. Dilute to 1X prior to use. 1X RIPA Lysis Buffer is intended for the extraction of cellular proteins for the efficient lysis of cells and solubilization of protein, while minimizing protein degradation and maintaining protein immunoreactivity and biological activity. We recommend using 1.0 ml of RIPA Lysis Buffer to lyse 0.5 to 5 x 10E7 adherent mammalian cells. This buffer contains ionic detergents and may not be suitable for kinase enzymes, if these enzymes are easily denatured. Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 1X RIPA lysis buffer consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) NP-40, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide at a pH
• Expiration Date: 12 months from date of receipt.

Comparison of miR-34a and target oncogene expression levels in 143B cells treated with bioengineered miR-34a prodrug (tRNA/mir-34a) and doxorubicin, alone or in combination. Cells were harvested at 72 h after treatment. Pre-miR-34a. (C) were measured by Western blot. Band density was determined by Image Lab software (Bio-Rad), and normalized to that of GAPDH. Cell lysates were prepared using RIPA buffer supplemented with the complete protease inhibitor cocktail, and protein concentrations were determined using a BCA Protein Assay Kit.

Representative picture above of Western blots from LV-free wall tissues in each group (control group, 10; MI group, 5; LL-TS group, 5) showed effects of LL-TS treatment on protein expression level of TGF-β1, MMP-9, collagen I, and collagen III. Transmural myocardial tissue sample ≈ 1 cm2 obtained from the LV free wall outside the infarction area was homogenized in radioimmunoprecipitation assay lysis buffer containing proteinase inhibitor.